Comparative Effectiveness of Tocilizumab as Monotherapy Versus TNF inhibitors in Combination with Conventional Synthetic Disease Modifying Antirheu-matic Drugs in Bio-naive Patients with Rheumatoid Arthritis

被引：0

作者：

Lauper, K. ^{[1
,2
]}

Kvien, T. K. ^{[3
]}

Codreanu, C. ^{[4
]}

Hernandez, M., V ^{[5
]}

Iannone, I. ^{[6
]}

Kristianslund, E. K. ^{[3
]}

Lukina, G. ^{[7
]}

Nordstrom, D. C. ^{[8
,9
]}

Pavelka, K. ^{[10
]}

Rotar, Z. ^{[11
]}

Santos, M. J. ^{[12
,13
]}

Gale, S. L. ^{[14
]}

John, M. ^{[15
]}

Luder, Y. ^{[15
]}

Courvoisier, D. S. ^{[1
]}

Gabay, C. ^{[1
,2
]}

机构：

[1] Geneva Univ Hosp, Geneva, Switzerland

[2] SCQM Registry, Zurich, Switzerland

[3] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway

[4] Univ Med & Pharm, Ctr Rheumat Dis, Bucharest, Romania

[5] Hosp Clin Barcelona, Rheumatol Dept, Barcelona, Spain

[6] Univ Hosp Bari, GISEA, Bari, Italy

[7] Inst Rheumatol, ARBITER, Moscow, Russia

[8] ROB FIN Helsinki Univ Hosp, Helsinki, Finland

[9] Univ Helsinki, Helsinki, Finland

[10] Charles Univ Prague, Prague, Czech Republic

[11] Univ Med Ctr Ljubljana, BioRx Si, Ljubljana, Slovenia

[12] Hosp Garcia de Orta, Rheumatol Dept, Almada, Portugal

[13] Reuma Pt, Lisbon, Portugal

[14] Genentech Inc, San Francisco, CA USA

[15] F Hoffmann La Roche, Basel, Switzerland

来源：

SWISS MEDICAL WEEKLY | 2018年 / 148卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SSRP 35

引用

页码：20S / 20S

页数：1

共 50 条

[1] COMPARATIVE EFFECTIVENESS OF TOCILIZUMAB AS MONOTHERAPY VERSUS TNF INHIBITORS IN COMBINATION WITH CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN BIONAIVE PATIENTS WITH RHEUMATOID ARTHRITIS
Lauper, K.
Kvien, T. K.
Codreanu, C.
Hernandez, M. V.
Ianonne, F.
Kristianslund, E. K.
Lukina, G.
Nordstrom, D. C.
Pavelka, K.
Rotar, Z.
Santos, M. J.
Gale, S. L.
John, M.
Luder, Y.
Courvoisier, D. S.
Gabay, C.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 320 - 321
[2] Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naive patients with rheumatoid arthritis
Lauper, Kim
Mongin, Denis
Iannone, Florenzo
Kristianslund, Eirik K.
Kvien, Tore K.
Nordstrom, Dan C.
Pavelka, Karel
Pombo-Suarez, Manuel
Rotar, Ziga
Santos, Maria J.
Codreanu, Catalin
Lukina, Galina
Gale, Sara L.
John, Markus
Luder, Yves
Courvoisier, Delphine S.
Gabay, Cem
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (01) : 17 - 24
[3] Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan- European TOCERRA register collaboration
Lauper, Kim
Nordstrom, Dan C.
Pavelka, Karel
Victoria Hernandez, Maria
Kvien, Tore K.
Kristianslund, Eirik Klami
Santos, Maria Jose
Rotar, Ziga
Iannone, Florenzo
Codreanu, Catalin
Lukina, Galina
Gale, Sara L.
Sarsour, Khaled
Luder, Yves
Courvoisier, Delphine Sophie
Gabay, Cem
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (09) : 1276 - 1282
[4] Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study
Deng, Daihua
Zhou, Jun
Li, Min
Li, Siyin
Tian, Lan
Zou, Jinmei
Wang, Tingting
Wu, Jianhong
Zeng, Fanxin
Yang, Jing
SCIENTIFIC REPORTS, 2020, 10 (01)
[5] Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study
Daihua Deng
Jun Zhou
Min Li
Siyin Li
Lan Tian
Jinmei Zou
Tingting Wang
Jianhong Wu
Fanxin Zeng
Jing Yang
Scientific Reports, 10
[6] RETENTION OF TOCILIZUMAB AS MONOTHERAPY VERSUS TNF INHIBITORS WITH CONVENTIONAL SYNTHETIC DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO TNF INHIBITORS: A STUDY FROM THE TOCERRA COLLABORATION
Lauper, K.
Nordstrom, D. C.
Pavelka, K.
Hernandez, V.
Santos, M. J.
Rotar, Z.
Iannone, F.
Codreanu, C.
Lukina, G.
Gale, S. L.
Sarsour, K.
Pethoe-Schramm, A.
Courvoisier, D. S.
Gabay, C.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 850 - 851
[7] Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
Kivitz, Alan
Olech, Ewa
Borofsky, Michael
Zazueta, Beatriz M.
Navarro-Sarabia, Federico
Radominski, Sebastiao C.
Merrill, Joan T.
Rowell, Lucy
Nasmyth-Miller, Clare
Bao, Min
Wright, Stephen
Pope, Janet E.
ARTHRITIS CARE & RESEARCH, 2014, 66 (11) : 1653 - 1661
[8] Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Hernandez-Cruz, Blanca
Marquez-Saavedra, Esther
Caliz-Caliz, Rafael
Navarro-Sarabia, Federico
ARTHRITIS RESEARCH & THERAPY, 2016, 18
[9] Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Blanca Hernández-Cruz
Esther Márquez-Saavedra
Rafael Caliz-Caliz
Federico Navarro-Sarabia
Arthritis Research & Therapy, 18
[10] ABATACEPT IN MONOTHERAPY OR IN COMBINATION WITH CONVENTIONAL DISEASE-MODIFYING DRUGS: TREATMENT PERSISTENCE IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS.
Munoz Reinoso, P.
Garcia Hernandez, I.
Hernandez-Cruz, B.
Perez Venegas, J. J.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1313 - 1314

← 1 2 3 4 5 →